IMMNOV — Immunovia AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK136.55m
- SEK80.94m
- SEK0.69m
Brief: Immunovia: Positive Results From The Immray Pancan-D Verification Study
Brief: Immunovia Appoints Patrik Dahlen As New CEO
Brief: Immunovia Q2 Loss Before Tax At SEK 34.1 Million
Brief: Immunovia Expands Its Lung Cancer Program Based On Encouraging Results From Current Discovery Study
Brief: Immunovia Completes Directed Issue And Raises About SEK 400 Mln
Brief: Immunovia Intends To Carry Out A Directed Share Issue Through An Accelerated Book Building Process
Brief: Immunovia Provides Update On COVID-19 Pandemic
Brief: Immunovia Provides Update On COVID-19 Pandemic
Brief: Immunovia And Global Pharmaceutical Company Agree On Early Termination Of Lung Cancer Collaboration
Brief: Immunovia Provides Update In Response To COVID-19 Pandemic
Brief: Immunovia Q4 Operating Loss Widens To SEK 29.6 Million
Brief: Immunovia Completes IMMray PanCan-d Commercial Test Model Study With High Accuracy
Brief: Immunovia Q3 Net Loss Widens To SEK 25.6 Mln
Brief: Immunovia Provides Update On Its Lung Cancer Pipeline Projects
Brief: Immunovia Q2 Loss Before Tax Widens To SEK 29.9 Million
Brief: Immunovia and Erlangen University Hospital Enter Into A Collaboration Agreement
Brief: Immunovia's CEO Sells 48,000 Immunovia Shares
Brief: Immunovia Appoints Pete Salzmann As CEO
Brief: Immunovia Announces Results From Immray PanCan-D Optimization Work